Brookline Capital Markets Comments on RVMD FY2027 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Stock analysts at Brookline Capital Markets issued their FY2027 EPS estimates for shares of Revolution Medicines in a research note issued on Monday, September 28th. Brookline Capital Markets analyst L. Cann expects that the company will earn ($5.00) per share for the year. Brookline Capital Markets has a “Buy” rating and a $318.00 price target on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($8.87) per share. Brookline Capital Markets also issued estimates for Revolution Medicines’ FY2028 earnings at $0.94 EPS, FY2029 earnings at $8.94 EPS and FY2030 earnings at $18.15 EPS.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same period in the previous year, the company earned ($1.31) EPS.

A number of other equities research analysts also recently weighed in on RVMD. TD Cowen upgraded Revolution Medicines to a “strong-buy” rating in a research report on Monday, August 24th. Raymond James Financial reiterated a “strong-buy” rating and issued a $248.00 price objective on shares of Revolution Medicines in a research report on Thursday, August 27th. Wedbush upped their target price on shares of Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a research report on Thursday, August 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Friday, July 17th. Finally, Guggenheim increased their price objective on shares of Revolution Medicines from $240.00 to $275.00 and gave the company a “buy” rating in a report on Friday, August 28th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $234.33.

Revolution Medicines Price Performance

RVMD opened at $204.48 on Wednesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The stock has a market capitalization of $43.83 billion, a P/E ratio of -23.18 and a beta of 1.40. The company’s 50 day simple moving average is $201.67 and its 200-day simple moving average is $164.83. Revolution Medicines has a one year low of $45.49 and a one year high of $224.31.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Meeder Advisory Services Inc. lifted its position in Revolution Medicines by 3.0% during the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock worth $401,000 after acquiring an additional 120 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Revolution Medicines by 147.7% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 218 shares of the company’s stock worth $41,000 after buying an additional 130 shares in the last quarter. Contravisory Investment Management Inc. bought a new position in Revolution Medicines during the 2nd quarter worth $32,000. ABS Investment Management LLC bought a new position in Revolution Medicines during the 2nd quarter worth $337,104,000. Finally, Johnson Financial Group Inc. acquired a new position in Revolution Medicines in the 2nd quarter valued at $37,000. 94.34% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Revolution Medicines news, CFO Jack Anders sold 4,053 shares of the company’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $807,519.72. Following the completion of the sale, the chief financial officer owned 119,216 shares of the company’s stock, valued at approximately $23,752,595.84. This represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Stephen Kelsey sold 5,569 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $1,109,567.56. Following the completion of the sale, the insider owned 286,307 shares in the company, valued at approximately $57,043,806.68. This trade represents a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 284,682 shares of company stock worth $58,147,464 over the last quarter. Insiders own 7.60% of the company’s stock.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers.